<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00260819</url>
  </required_header>
  <id_info>
    <org_study_id>P050502</org_study_id>
    <secondary_id>AOR05038</secondary_id>
    <nct_id>NCT00260819</nct_id>
  </id_info>
  <brief_title>Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia</brief_title>
  <official_title>Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Excessive rise in pulmonary artery pressure induced by low oxygen tension (hypoxia) is one of&#xD;
      the factors implicated in high-altitude pulmonary oedema. Plasma ET1 increases in subjects&#xD;
      exposed to high altitude and is correlated to pulmonary artery pressure.&#xD;
&#xD;
      The aim of the study is to investigate whether blockade of ET1 receptors would reduce the&#xD;
      acute rise in systolic pulmonary artery pressure induced by hypoxia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be examined on a variable load supine bicycle ergometer. The exercise table&#xD;
      will be tilted laterally by 20 to 30 degrees to the left. PASP will be assessed using Doppler&#xD;
      echocardiography at rest and during during supine bicycle exercise in NORMOXIA and hypoxia.&#xD;
      Exposure to normobaric hypoxia will be performed by breathing a hypoxic gas mixture at sea&#xD;
      level during 90 minutes (12,3 % O2 + 87.7 % N2) reproducing conditions at 4300 m altitude.&#xD;
      Exercise will be started at an initial workload of 40 watts and increased by 10 watts every&#xD;
      minute to reach a workload level defined by a heart rate (HR) corresponding to 50% of the&#xD;
      estimated maximal aerobic power&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate whether bosentan compared to placebo reduces hypoxia-induced increase in pulmonary artery pressure in healthy subjects and in subjects with past history of high-altitude pulmonary oedema</measure>
    <time_frame>during the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary artery pressure response to exercise,</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exercise capacity,</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygen desaturation,</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>and to assess the global safety</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hypoxia-Induced Pulmonary Artery Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental and Placebo Comparator administered in random order during to successive experimental phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Experimental and Placebo Comparator administered in random order during to successive experimental phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <description>Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo</description>
    <arm_group_label>1</arm_group_label>
    <other_name>TRACLEER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentam TRACLEER</intervention_name>
    <description>Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20 non smoker healthy volunteers : 10 resistant to high-altitude pulmonary oedema and&#xD;
             10 susceptible subjects, without history of cardiac or pulmonary disease or asthma,&#xD;
             after a complete clinical examination and safety laboratory measurements prior to&#xD;
             randomization, and after giving informed written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  antecedent of lung disease notably with asthmatic antecedent or HTAP&#xD;
&#xD;
          -  antecedent of heart disease&#xD;
&#xD;
          -  female genital organ&#xD;
&#xD;
          -  systolic blood pressure &lt; 85 mmHg or &gt; 160 mmHg after 5 minutes of lengthened rest.&#xD;
&#xD;
          -  sentimentality in a medicine, in particular in a bosentan or in one of the excipients&#xD;
             of the tablet.&#xD;
&#xD;
          -  hepatic incapacity moderated to severe correspondent in the class B or C of the&#xD;
             classification of Child-Pugh (cf Pharmacokinetics) Rate serous hepatic&#xD;
             aminotransferases, aspartate aminotransferases( ASAT) and\or alanine aminotransférases&#xD;
             ( ALAT), superior to 3 times the superior limit of the normal before the started of&#xD;
             the treatment.&#xD;
&#xD;
          -  pointed or chronic systematic diseases.&#xD;
&#xD;
          -  presence of antibody anti-HIV, of anti-HVC antibody, antigens Hbs and\or antibody&#xD;
             anti-Hbc. - active addiction to smoking.&#xD;
&#xD;
          -  alcohol abuse and of toxins.&#xD;
&#xD;
          -  Taking of concomitant medicines except those allowed the chapter concomitant&#xD;
             treatments.&#xD;
&#xD;
          -  signs, symptoms or values of the biological examinations situated except the&#xD;
             clinically acceptable values for healthy subjects with or without antecedent of OPHA.&#xD;
&#xD;
          -  common(current) ingestion of excessive quantities of tea, coffee(cafe), chocolate&#xD;
             and\or drinks containing some caffeine (&gt; 5 cups / day, is approximately 500 mg of&#xD;
             caffeine a day).&#xD;
&#xD;
          -  consumption of juice of grapefruit and\or herb tea on base of St.&#xD;
&#xD;
          -  John's wort&#xD;
&#xD;
          -  Don of blood in 3 months preceding the study.&#xD;
&#xD;
          -  Persons in period of exclusion on the national file of the persons lending itself to&#xD;
             the biomedical search(research) without direct individual profit.&#xD;
&#xD;
          -  refusal or linguistic or psychic incapacity to sign the lit(enlightened) assent.&#xD;
&#xD;
          -  subject which can not submit itself to the constraints of the protocol (for example,&#xD;
             not cooperative, incapable to go(surrender) to the visits of follow-up and probably&#xD;
             incapable to finish the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel AZIZI, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique 9201 Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908 cedex 15</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Grünig E, Mereles D, Hildebrandt W, Swenson ER, Kübler W, Kuecherer H, Bärtsch P. Stress Doppler echocardiography for identification of susceptibility to high altitude pulmonary edema. J Am Coll Cardiol. 2000 Mar 15;35(4):980-7.</citation>
    <PMID>10732898</PMID>
  </results_reference>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>December 1, 2005</study_first_submitted>
  <study_first_submitted_qc>December 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2005</study_first_posted>
  <last_update_submitted>October 16, 2008</last_update_submitted>
  <last_update_submitted_qc>October 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Isabelle Brindel</name_title>
    <organization>Department Clinical Research of Developpement</organization>
  </responsible_party>
  <keyword>Hypoxia-induced pulmonary artery hypertension</keyword>
  <keyword>High-altitude pulmonary oedema</keyword>
  <keyword>ETA receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

